Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million

Reuters11-06

Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million

Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569879-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581060567?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581060567","market":"nz","top_or_hot":-1,"title":"Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 cash position of $39.8 million and R&amp;D expenses of $3.8 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569879-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 cash position of $39.8 million and R&amp;D expenses of $3.8 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569879-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLcfxPsp:1","article_id":"2581060567","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581060567","pubTimestamp":1762432237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","CGTX":"Cognition Therapeutics, Inc","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Cognition Therapeutics报告第三季度现金状况为3980万美元，研发费用为380万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGTX":0.9,"NDAQ":0.9},"content_text":"Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million\n    \n\n        Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569879-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581060567","isCrawlerRequest":true}